Is there a scientific basis for the therapeutic effects of Serenoa repens in benign prostatic hyperplasia? Mechanisms of action

Journal of Urology

Volumn 172, Issue 5 I, 2004, Pages 1792-1799

  Buck, A C ^a,b  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b Brownlee House   (United Kingdom)

Author keywords

Prostate prostatic hyperplasia

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANDROGEN RECEPTOR; ESTROGEN RECEPTOR; GROWTH FACTOR; HEXANE; ICOSANOID; PLANT EXTRACT; PROLACTIN; PYGEUM AFRICANUM EXTRACT; SABAL EXTRACT; STEROID 5ALPHA REDUCTASE INHIBITOR;

COMPARATIVE STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; HERBAL MEDICINE; HUMAN; ICOSANOID METABOLISM; IN VITRO STUDY; IN VIVO STUDY; MALE; MEDLINE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PYGEUM; REVIEW; SABAL; URINARY TRACT OBSTRUCTION;

EID: 5444256882     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000140503.11467.8e     Document Type: Review

References (67)

1. Wetzel, M. S., Eisenberg, D. M. and Kaptchuk, T. J.: Courses involving complimentary and alternative medicine at U.S. medical schools. JAMA, 280: 784, 1998
2. Marcus, D. M. and Grollman, A. P.: Botanical medicines-the need for new regulation. N Engl J Med, 347: 2073, 2002
3. Murray, M. T. and Pizzorno, J.: Encyclopedia of Natural Medicine. Seattle: John Bastyr University Publishing, 1994
4. Crellin, J. K. and Philpott, J.: A Reference Guide to Medicinal Plants: Herbal Medicine Past and Present. Durham, North Carolina: Duke University Press, 1990
5. American Hospital Formulary Service, 8th ed. Washington, D. C.: American Pharmaceutical Association, pp. 457-459, 2004
6. Chavez, M. L. and Chavez, P. I.: Saw palmetto. Hosp Pharmacy, 33: 1335, 1998
7. Wilt, T. J., Ishani, A., Rutks, I. and MacDonald, R.: Phytotherapy for benign prostatic hyperplasia. Public Health Nutr, 3: 459, 2000
8. Gerber, G. S.: Saw palmetto for the treatment of men with lower urinary tract symptoms. J Urol, 163: 1408, 2000
9. Boyle, P., Robertson, C., Lowe, F. and Roehrborn, C.: Meta-analysis of clinical trials of permixon in the treatment of symptomatic benign prostatic hyperplasia. Urology, 55: 533, 2000
10. Fagelman, E. and Lowe, F. C.: Herbal medications in the treatment of benign prostatic hyperplasia (BPH). Urol Clin North Am, 29: 23, 2002
11. Sultan, C., Terraza, A., Devillier, C., Carilla, E., Briley, M., Loire, C. and Descomps, B.: Inhibition of androgen metabolism and binding by a liposterolic extract of "Serenoa repens B" in human foreskin fibroblasts. J Steroid Biochem, 20: 515, 1984
12. Duker, E.-M., Kopanski, L. and Schweikert, H.-U.: Inhibition of 5 a reductase activity by extracts from Sabal serrulata. Planta Med, 55: 587, 1989
13. Carilla, E., Briley, M., Fauran, F., Sultan, C. and Duvilliers, C.: Binding of Permixon, a new treatment for prostatic benign hyperplasia, to the cytosolic androgen receptor in the rat prostate. J Steroid Biochem, 20: 521, 1984
14. Bayne, C. W., Donnelly, F., Chapman, K., Bollina, P., Buck, C. and Habib, F.: A novel coculture model for benign prostatic hyperplasia expressing both isoforms of 5 alpha-reductase. J Clin Endocrinol Metab, 83: 206, 1998
15. Bayne, C. W., Donnelly, F., Ross, M. and Habib, F. K.: Serenoa repens (Permixon): a 5alpha-reductase types I and II inhibitor-new evidence in a coculture model of BPH. Prostate, 40: 232, 1999
16. Sargent, N. S. and Habib, F. K.: Partial purification of human prostatic 5alpha-reductase (3-oxo-5 alpha-steroid: NADP+4-ene-oxido-reductase; EC 1.3.1.22) in a stable and active form. J Steroid Biochem Mol Biol, 38: 73, 1991
17. Savory, J. G., May, D., Reich, T., La Casse, E. C., Lakins, J., Tenniswood, M. et al: 5alpha-reductase type I is localized to the outer nuclear membrane. Mol Cell Endocrinol, 110: 137, 1995
18. Ravenna, L., Di Silverio, F., Russo, M. A., Salvatori, L., Morgante, E., Marone, S. et al: Effects of the lipidosterolic extract of Serenoa repens (Permixon) on human prostatic cell lines. Prostate, 29: 219, 1996
19. Neiderprum, H.-J., Schweikert, H.-U. and Zanker, K. S.: Testosterone 5 α reductase inhibition by free fatty acids from Sabal serrulata fruits. Phytomedicine, 1: 127, 1994
20. Rhodes, L., Primka, R. L., Berman, C., Vergult, G., Gabrielm, G., Pierre-Malice, M. et al: Comparison of finasteride (Proscar) 5 alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5alpha reductase inhibition. Prostate, 22: 43, 1993
21. Wang, L. G., Liu, X. M., Kreis, W. and Budman, D. R.: Down-regulation of prostate-specific antigen expression by finasteride through inhibition of complex formation between androgen receptor and steroid receptor-binding consensus in the promoter of the PSA gene in LNCaP cells. Cancer Res, 57: 714, 1997
22. Iehle, C., Delos, S., Guirou, O., Tate, R., Raynaud, J. P. and Martin, P. M.: Human prostatic steroid 5 alpha-reductase isoforms - a comparative study of selective inhibitors. J Steroid Biochem Molec Biol, 54: 273, 1995
23. Delos, S., Iehle, C., Martin, P. M. and Raynaud, J. P.: Inhibition of the activity of 'basic' 5 alpha-reductase (type 1) detected in DU 145 cells and expressed in insect cells. J Steroid Biochem Mol Biol, 48: 347, 1994
24. Delos, S., Carsol, J. L., Ghazarossian, E., Raynaud, J. P. and Martin, P. M.: Testosterone metabolism in primary cultures of human prostate epithelial cells and fibroblasts. J Steroid Biochem Mol Biol, 55: 375, 1995
25. Bayne, C. W., Ross, M., Donnelly, F. and Habib, F. K.: The selectivity and specificity of the actions of the lipidpo-sterolic extract of serenoa repens (Permixon®) on the prostate. J Urol, 164: 876, 2000
26. Weisser, H., Behnke, B., Helpap, B., Bach, D. and Krieg, M.: Enzyme activities in tissue of human benign prostatic hyperplasia after three months' treatment with the Sabal serrulata extract IDS 89 (Strogen) or placebo. Eur Urol, 31: 97, 1997
27. Di Silverio, F., Monti, S., Sciarra, A., Varasano, P. A., Martini, C., Lanzara, S. et al: Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate, 37: 77, 1998
28. Weisser, H., Tunn, S., Behnke, B. and Krieg, M.: Effects of the sabal serrulata extract IDS 89 and its subfractions on 5 alpha-reductase activity in human benign prostatic hyperplasia. Prostate, 28: 300, 1996
29. Kozak, J., Bartsch, W., Krieg, M. and Voigt, K. D.: Nuclei of stroma: site of highest estrogen concentration in human benign prostatic hyperplasia. Prostate, 3: 433, 1982
30. Moore, R. J., Gazak, J. M. and Wilson, J. D.: Regulation of cytoplasmic dihydrotestosterone binding in dog prostate by 17 beta-estradiol. J Clin Invest, 63: 351, 1979
31. Habernicht, U. F., Tunn, U. W., Senge, T., Schroder, F. H., Schweikert, H. U., Bartsch, G. et al: Management of benign prostatic hyperplasia with particular emphasis on aromatase inhibitors. J Steroid Biochem Molec Biol, 44: 557, 1993
32. Larsson, B., Andersson, K. E., Batra, S., Mattiason, A. and Sjogren, C.: Effects of estradiol on norepinephrine-induced contraction, alpha adrenoreceptor number and norepinephrine content in the female rabbit urethra. J Pharmacol Exp Ther, 229: 557, 1984
33. Naslund, M. J. and Coffey, D. S.: The differential effects of neonatal androgen, estrogen and progesterone on adult rat prostate growth. J Urol, 136: 1136, 1986
34. Tangbanleukal, L. and Robinette, C. L.: Prolactin mediates estradiol-induced inflammation in the lateral prostate of Wistar rats. Endocrinology, 132: 2407, 1993
35. Paubert-Braquet, M., Richardson, F. O., Servent-Saez, N., Gordon, W. C., Monge, M.-C., Bazan, N. G. et al: Effect of Serenoa repens extract (Permixon) on estradiol/testosterone-induced experimental prostate enlargement in the rat. Pharmacol Res, 34: 171, 1996
36. Negro-Vilar, A., Saad, W. A. and McCann, S. M.: Evidence for a role in prolactin in prostate and seminal vesicle growth in immature male rats. Endocrinology, 100: 729, 1977
37. Smith, C., Assimos, D., Lee, C. and Grayhack, J. T.: Metabolic action of prolactin in regressing prostate: independent of androgen action. Prostate, 6: 49, 1985
38. Grayhack, J. T., Bunce, P. L., Kearns, J. W. and Scott, W. W.: Influence of the pituitary on prostatic response to androgen in the rat Bull. Johns Hopkins Hosp, 96: 154, 1955
39. Prins, G. S.: Prolactin influence on cytosol and nuclear androgen receptors in the ventral, dorsal, and lateral lobes of the rat prostate. Endocrinology, 120: 1457, 1987
40. Blankenstein, M. A., Bolt-de-Vries, J. and Schroder, F. H.: Binding of prolactin to membranes from human prostate. Advances in Urological Oncology and Endocrinology. Acta Med Ed Congr, pp. 71-82, 1984
41. Vacher, P., Prevarskaya, N., Skyrma, R., Audy, M. C., Vacher, A. M., Odessa, M. F. et al: The lipidosterolic extract from Serenoa repens interferes with prolactin receptor signal transduction. J Biomed Sci, 2: 357, 1995
42. Van Coppenolle, F., Le Bourhis, X., Carpentier, F., Delaby, G., Cousse, H., Raynaud, J. P. et al: Pharmacological effects of the lipidosterolic extract of Serenoa repens (Permixon) on rat prostate hyperplasia induced by hyperprolactinaemia: comparison with finasteride. Prostate, 43: 49, 2000
43. Theyer, G., Kramer, G., Assmann, I., Sherwood, E., Preinfalk, W., Marberger, M. et al: Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest, 66: 96, 1992
44. Kramer, G., Steiner, G. E., Handisurya, A., Stix, U., Haitel, A., Knerer, B. et al: Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal proliferation. Prostate, 52: 43, 2002
45. Varshavski, S. V: Application of prostaglandin inhibitors in the therapy of BPH. Eur Urol Today, 13: 14, 2002
46. Paubert-Braquet, M., Mencia Huerta, J. M., Cousse, H. and Braquet, P.: Effect of the lipidic extract of Serenoa repens (Permixon) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphnuclear neutrophils. Prostaglandins Leukot Essent Fatty Acids, 57: 299, 1997
47. Vella-Navarette, R., Garcia Cardoso, J., Barat, A., Manzarbeitia, F. and Lopez Farre, A.: Effects of the lipido sterolic extract of Serenoa repens (Permixon) on the infiltrating cells and inflammatory markers in prostatic tissue from BPH patients. Eur Urol, 1: 62, 2002
48. Breu, W., Hagenlocher, M., Redl, K., Tittel, G., Stadler, F. and Wagner, H.: Anti-inflammatory activity of sabal fruit extracts prepared with supercritical carbon dioxide. In vitro antagonists of cyclooxygenase and 5-lipoxygenase metabolism. Arzneimittelforschung, 42: 547, 1992
49. Ragab, A., Ragab-Thomas, J. M. F., Delhon, A., Tisne-Versailles, J., Gassama-Diagne, A., Fauvel, J., Couzinier, J. P. et al: Effects of Permixon® (Sereprostat® in Spain) on phospholipase A2 activity and on arachidonic acid metabolism in cultured prostatic cells. Edited by F. DiSilverio and A. Steg. In: New Trends in Bladder Cancer Chemotherapy. New Trends in BPH Etiopathies. Rome, Italy: Acta Medica Roma, pp. 293-296, 1987
50. Lee, C., Kozlowski, J. M. and Grayhack, J. T.: Intrinsic and extrinsic factors controlling benign prostatic growth. Prostate, 31: 131, 1997
51. Cardillo, M., Berchem, G., Tarkington, M. A., Krajewski, S., Krajewski, M., Reed, J. C. et al: Resistance to apoptosis and up regulation of Bcl-2 in benign prostatic hyperplasia after androgen deprivation. J Urol, 158: 212, 1997
52. Colombel, M., Vacherot, F., Diez, S. G., Fontaine, E., Buttyan, R. and Chopin, D.: Zonal variation of apoptosis and proliferation in the normal prostate and in benign prostatic hyperplasia. Br J Urol, 82: 380, 1998
53. Perlman, H., Zhang, X., Chen, M. W., Walsh, K. and Buttyan, R.: An elevated bax/bcl-2-ratio corresponds with the onset of prostate epithelial cell apoptosis. Cell Death Differ, 6: 48, 1999
54. Ilio, K. Y., Park, I. I., Pins, M. R., Kozlowski, J. M. and Lee, C.: Apoptotic activity of doxazocin on prostate stroma in vitro is mediated through an autocrine expression of TGF beta1. Prostate, 48: 131, 2001
55. Vacherot, F., Azzouz, M., Gil-Diez-De-Medina, S., Colombel, M., De LaTaille, A., Lefrere Belda, M.-A. et al: Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSESr, Permixon®) in benign prostatic hyperplasia. Prostate, 45: 259, 2000
56. Wijsman, J. H., Jonker, R. R., Keijzer, R., van de Velde, C. J., Cornelisse, C. J. and van Dierendonck, J. H.: A new method to detect apoptosis in paraffin sections: in situ end-labelling of fragmented DNA. J Histochem Cytochem, 41: 7, 1993
57. Gelman, A. P.: Oncogenes and growth factors in prostate cancer. J Natl Inst Health Research, 3: 60, 1991
58. Mori, H., Maki, M., Oishi, K, Jaye, M., Igarashi, K., Yoshida, O. et al: Increased expression of genes for basic fibroblast growth factor and transforming growth factor type beta 2 in human benign prostatic hyperplasia. Prostate, 16: 71, 1990
59. Yan, G., Fukabori, Y., Nikolaropolous, S., Wang, F. and McKeehan, W. L.: Heparin-binding keratinocyte growth factor is a candidate stromal-to-epithelial- cell andromedin. Mol Endocrinol, 6: 2123, 1992
60. Paubert-Braquet, M., Cousse, H., Raynaud, J. P., Mencia-Huerta, J. M. and Braquet, P.: Effect of the lipidosterolic extract of Serenoa repens (Permixon) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsies. Eur Urol, 33: 340, 1998
61. Maddy, S. Q., Chisholm, G. D., Hawkins, R. A. and Habib, F. K.: Localization of epidermal growth factor receptors in the human prostate by biochemical and immunocytochemical methods. J Endocrinol, 113: 147, 1987
62. Ibrahim, G. K., Kerns, B.-J. M., MacDonald, J. A., Ibrahim, S. N., Kinney, R. B., Humphrey, P. A. et al: Differential immunore-activity of epidermal growth factor receptor in benign, dysplastic and malignant prostatic tissues. J Urol, 149: 170, 1993
63. Lowe, F. C. and Fagelman, E.: Phytotherapy in the treatment of benign prostatic hyperplasia. Curr Opin Urol, 8: 27, 1998
64. De Smet, P. A.: Herbal remedies. N Engl J Med, 347: 2046, 2002
65. Buck, A. C.: Phytotherapy for the prostate. Br J Urol, 78: 325, 1996
66. Carraro, J. C., Raynaud, J. P., Koch, G., Chisholm, G. D., Di Silverio, F., Teillac, P. et al: Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomised international study of 1,098 patients. Prostate, 20: 231, 1996
67. Debrayne, F., Koch, G, Boyle, P., Da Silva, F. C., Gillenwater, J. G., Hamdy, F. C. et al: Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Eur Urol, 41: 497, 2002